Tatar Luiza, Bandargal Saruchi, Pusztaszeri Marc P, Forest Véronique-Isabelle, Hier Michael P, Kouz Jasmine, Chowdhury Raisa, Payne Richard J
Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 0G4, Canada.
Department of Pathology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Cancers (Basel). 2025 Aug 1;17(15):2553. doi: 10.3390/cancers17152553.
: Papillary thyroid microcarcinoma (MPTC), a subset of papillary thyroid carcinoma (PTC), is increasingly detected with advanced imaging. While most MPTCs are indolent, some exhibit aggressive behavior, complicating clinical management. The mutation, common in PTC, is linked to aggressive features, and its allele frequency (AF) may serve as a biomarker for tumor aggressiveness. This study explored the association between AF and aggressive histopathological features in MPTC. : Data from 1 January 2016 to 23 December 2023 were retrieved from two McGill University teaching hospitals. Inclusion criteria comprised patients aged ≥ 18 years with thyroid nodules ≤ 1 cm, documented mutation and AF results, and available surgical pathology reports. Tumor aggressiveness was defined as the presence of lymph node metastasis, aggressive histological subtype (tall cell, hobnail, columnar, solid/trabecular or diffuse sclerosing), extra thyroidal extension, or extensive lymphovascular extension. Associations were explored using -tests. : Among 1564 records, 34 met the inclusion criteria and were included in analyses. The mean AF was significantly higher in aggressive tumors (23.58) compared to non-aggressive tumors (13.73) (95% CI: -18.53 to -1.16, = 0.03). Although not statistically significant, trends were observed for higher AF in tumors with lymph node metastasis (mean AF: 25.4) compared to those without (mean AF: 16.67, = 0.08). No significant difference was noted in AF by histological subtype (mean AF for aggressive: 19.57; non-aggressive: 19.15, = 0.94). : Elevated AF is associated with aggressive behavior in MPTC, highlighting its potential as a biomarker to inform treatment strategies. Larger studies are warranted to validate these findings and enhance clinical management of MPTC patients.
甲状腺微小乳头状癌(MPTC)是甲状腺乳头状癌(PTC)的一个亚型,随着先进成像技术的应用,其检出率日益增加。虽然大多数MPTC生长缓慢,但有些表现出侵袭性行为,这使临床管理变得复杂。BRAF突变在PTC中很常见,与侵袭性特征相关,其等位基因频率(AF)可作为肿瘤侵袭性的生物标志物。本研究探讨了MPTC中BRAF AF与侵袭性组织病理学特征之间的关联。:从麦吉尔大学的两家教学医院检索了2016年1月1日至2023年12月23日的数据。纳入标准包括年龄≥18岁、甲状腺结节≤1 cm、有BRAF突变和AF结果记录以及有可用手术病理报告的患者。肿瘤侵袭性定义为存在淋巴结转移、侵袭性组织学亚型(高细胞型、鞋钉型、柱状型、实性/小梁型或弥漫性硬化型)、甲状腺外侵犯或广泛的淋巴管侵犯。使用t检验探索关联。:在1564条记录中,34条符合纳入标准并纳入分析。与非侵袭性肿瘤(13.73)相比,侵袭性肿瘤的平均BRAF AF显著更高(23.58)(95%CI:-18.53至-1.16,P = 0.03)。虽然无统计学意义,但观察到有淋巴结转移的肿瘤(平均AF:25.4)与无淋巴结转移的肿瘤(平均AF:16.67,P = 0.08)相比,BRAF AF有升高趋势。BRAF AF在不同组织学亚型之间无显著差异(侵袭性亚型平均AF:19.57;非侵袭性亚型:19.15,P = 0.94)。:BRAF AF升高与MPTC的侵袭性行为相关,突出了其作为指导治疗策略的生物标志物的潜力。需要更大规模的研究来验证这些发现并加强MPTC患者的临床管理。